Androgen deprivation + anti-PD1 trial for #prostatecancer.

"These data provide a reasonable therapeutic rationale to combine ADT with immunotherapy, thus leveraging anti-tumor immunity while mitigating the ADT-mediated induction of suppressive mechanisms. To that end, we designed and initiated the PRIME-CUT Phase II trial (NCT03951831) treating men with metastatic castration-sensitive prostate cancer (mCSPC) with a combination of standard of care chemo-hormonal therapy and anti-PD-1 immunotherapy using the anti-PD-1 immunotherapy cemiplimab."
#immunology #immunotherapy

https://www.cell.com/cancer-cell/fulltext/S1535-6108(23)00362-8